title: Acquired DNA mutations associated with in vivo hydroxyurea exposure.
abstract: Hydroxyurea (HU) is an effective therapeutic agent for patients with myeloproliferative disorders (MPDs) or sickle cell disease (SCD). Short-term HU toxicities primarily include transient myelosuppression, but long-term HU risks have not been defined. The mutagenic and carcinogenic potential of HU is not established, although HU has been associated with an increased risk of leukemia in some patients with MPD. In this study, 2 assays were used to quantitate acquired somatic DNA mutations in peripheral blood mononuclear cells (PBMCs) after in vivo HU exposure. The HPRT assay measures hypoxanthine phosphoribosyl transferase (hprt) mutations, while the VDJ assay identifies "illegitimate" T-cell receptor Vgamma-Jbeta interlocus recombination events. PBMCs were analyzed from patients with MPD, adults and children with SCD, and normal controls. MPD patients with prolonged HU exposure had numbers of DNA mutations equivalent to patients with low HU exposure or controls. Similarly, adults with SCD had equivalent numbers of DNA mutations regardless of HU exposure. Children with SCD and 30-month HU exposure had equivalent hprt(-) mutations but significantly more VDJ mutations (1.82 +/- 1.20 events per microg DNA) than children with 7-month HU exposure (1.58 +/- 0.87 events) or no HU exposure (1.06 +/- 0.45 events), P =.04 by analysis of variance. Taken together, these data suggest that the mutagenic and carcinogenic potential of in vivo HU therapy is low. Although increased numbers of illegitimate VDJ recombination events do not directly portend leukemia, young patients with SCD and HU exposure should be monitored serially for increases in DNA mutations.
authors.affiliation: Division of Hematology/Oncology, Department of Pediatrics, Duke University Medical Center, Durham, NC 27710, USA.
authors.forename: V N
authors.initials: VN
authors.lastname: Hanft
authors.forename: S R
authors.initials: SR
authors.lastname: Fruchtman
authors.forename: C V
authors.initials: CV
authors.lastname: Pickens
authors.forename: W F
authors.initials: WF
authors.lastname: Rosse
authors.forename: T A
authors.initials: TA
authors.lastname: Howard
authors.forename: R E
authors.initials: RE
authors.lastname: Ware
mesh_terms: D000328:Adult; D000755:Anemia, Sickle Cell / Q000097:blood / Q000188:drug therapy* / Q000235:genetics; D000970:Antineoplastic Agents / Q000009:adverse effects; D000986:Antisickling Agents / Q000009:adverse effects*; D002648:Child; D004247:DNA / Q000187:drug effects / Q000235:genetics*; D006801:Humans; D006918:Hydroxyurea / Q000009:adverse effects*; D007041:Hypoxanthine Phosphoribosyltransferase / Q000097:blood / Q000235:genetics*; D007963:Leukocytes, Mononuclear / Q000187:drug effects; D016296:Mutagenesis; D009153:Mutagens; D009196:Myeloproliferative Disorders / Q000097:blood / Q000188:drug therapy* / Q000235:genetics; D011995:Recombination, Genetic / Q000187:drug effects
chemical_list: D000970:Antineoplastic Agents; D000986:Antisickling Agents; D009153:Mutagens; D004247:DNA; D007041:Hypoxanthine Phosphoribosyltransferase; D006918:Hydroxyurea